Merger and acquisition intelligence - Intelligence on target company as part of due diligence

Background and objectives

Our client, in association with a leading investment banker, was targeting a company that had a Low Molecular Weight Heparins (LMWH) in a late stage of development, with a view to a potential take-over, without alerting the target.

• Primary requirement was the assessment of the molecule for valuation
• Strength of their clinical trial and likelihood of successful registration and pricing potential
• Additional query to determine the realistic timeline for competing drugs' registration

Approach

Our approach focused on the clinical trial centres, lead investigators and CRAs:

• Multiple US and EU clinical and principal investigators were targeted
• Targets included limited number of personnel from the target company itself
• KOLs were approached to establish the status of competing compounds' development status

Results delivered

The output included all the priority 1 and 2 KITs

• Status of the clinical trial and early indication of end points
• Timelines for development
• Likely pricing scenarios
• Potential uptake scenario for valuation modelling